Clinical trials: Neoplasm, Ovarian
Breast Cancer, Chronic Myeloproliferative Disorders
Campath-1H + FK506 and Methylprednisolone for GVHD
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00109993
- Testing
- alemtuzumab, methylprednisolone, tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Ovarian Cancer
Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer
In patients with an ovarian cancer, the treatment is currently based on surgery and chemotherapy. The impact of chemotherapy on the expansion and functional abilities of Vgamma9Vdelta2 T cells has never been evaluated.
- Trial name
- IClyCO (NCT01606358)
- Testing
- Carboplatin and / or taxol chemotherapy
- Where
- France
- Sponsor
- Rennes University Hospital
Ovarian Cancer, Fallopian Tube Cancer
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies or head…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- COTI2-101 (NCT02433626)
- Testing
- COTI2, Cisplatin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Critical Outcome Technologies Inc.
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This early phase I trial studies giving propranolol hydrochloride with standard chemotherapy in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT01504126
- Testing
- Chemotherapy, Propranolol Hydrochloride, Quality-of-Life Assessment
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Polycystic Ovary Syndrome, Hypothalamic-Pituitary-Ovarian Axis Dysfunction (Disorder)
Subclinical Hypothyroidism and Normogonadotropic Anovulation
Thyroid hormones (TH) can modify the functioning of the hypothalamic-pituitary-ovarian axis, affecting the functions of granulosa cells and the development and apoptosis of preantral follicles.
- Trial name
- NCT05782725
- Testing
- Comparison of laboratory test results in women in the 4 study arms
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Jagiellonian University
Fallopian Tube Cancer, Ovarian Cancer
Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: It is not yet known if treatment for recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer is more effective if it is begun when blood levels of CA 125 become elevated rather than waiting for other…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00002895
- Testing
- chemotherapy
- Where
- 21 sites in Austria, Belgium and 8 more
- Volunteers
- 1,400 people
- Sponsor
- Medical Research Council
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT05420545
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Breast Cancer, Ovarian Cancer
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
This is an extension study to evaluate the safety of Veliparib monotherapy or in combination with Carboplatin plus Paclitaxel or modified Folinic Acid/Fluorouracil/Irinotecan (FOLFIRI) in subjects with solid tumors.
- Conditions
- Breast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer
- Trial name
- NCT02033551
- Testing
- Veliparib, Carboplatin, Paclitaxel
- Where
- 5 sites in United States, Netherlands and 1 more
- Volunteers
- 47 people
- Sponsor
- AbbVie
Ovarian Carcinoma
Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin
The main purpose of this study is to determine the safety and tolerability of giving both paclitaxel and carboplatin in the abdominal cavity by looking at what effects (good and bad) this route of administration has on patients…
- Trial name
- NCT00181701
- Testing
- Paclitaxel, Carboplatin
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Ovarian Cancer, Ovarian Neoplasms
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
This is a phase II/III randomized controlled trial to evaluate efficacy of platinum-based chemotherapy vs conventionally prescribed non-platinum monochemotherapy in patients with platinum-resistant ovarian cancer
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Serous Adenocarcinoma, BRCA1 Mutation
- Trial name
- EPITOC (NCT04055038)
- Testing
- Platinum-Based Drug, Conventional chemotherapy
- Where
- Russia
- Volunteers
- 164 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Breast Cancer, Ovarian Cancer
Analyzing the Composition of Tears to Identify Cancer
This study will further evaluate the use of protein identification or protein pattern (signature) found in tears. We hypothesize that differences exist between the protein profile in tear fluid from patients with versus without…
- Conditions
- Breast Cancer, Ovarian Cancer, Colon Cancer, Benign Disease
- Trial name
- ACT (NCT00574678)
- Testing
- Tear collection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Arkansas
Carcinomatosis, Peritoneal
Inferior Epigastric Lymp Node (IELN) Basin as a Possible Systemic Metastatic Pathway of Ovarian Peritoneal Metastases
The IELN basin could represent a primary LN relay for systemic metastatic dissemination in patients with OPM. This newly described lymphatic pathway of metastatic dissemination of OPM may be involved in certain presentations of…
- Trial name
- OvEpiLyPath (NCT06237582)
- Testing
- epigastric lymph node biopsy
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Jules Bordet Institute
Ovarian Neoplasms, Endometrial Neoplasms
DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics
This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Endometrial Cancer, Ovarian Cancer
- Trial name
- DOvEEgene (NCT02288676)
- Where
- Canada
- Volunteers
- 1,200 people
- Sponsor
- McGill University
Ovarian Cancer, Fallopian Tube Cancers
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- NCT07472140
- Testing
- PARP inhibitor + Bevacizumab, PARP inhibitor
- Where
- Belarus
- Volunteers
- 120 people
- Sponsor
- N.N. Alexandrov National Cancer Centre
Breast Cancer, Biliary Tract Carcinoma
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
- Conditions
- Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT05123482
- Testing
- AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib)
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 460 people
- Sponsor
- AstraZeneca
Uterine Cervical Neoplasms, Ovarian Neoplasms
Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy
To evaluate whether formal referral to The Symptom Management and Supportive Care Clinic improves symptom burden in advanced stage or recurrent gynecologic oncology chemotherapy patients compared with symptom management performed…
- Conditions
- Uterine Cervical Neoplasms, Ovarian Neoplasms, Gynecologic Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT02786524
- Testing
- Specialized Symptom Management and Supportive Care
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- University of Michigan
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE
Polycystic Ovary Syndrome
Reproductive Endocrinology Oxford Study (RepOx)
This is a prospective observational study that aims to identify the underlying mechanisms of PolyCystic Ovarian Syndrome (PCOS) and associated comorbidities such as subfertility, miscarriage; and pregnancy complications such as…
- Trial name
- RepOx (NCT05177562)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 1,175 people
- Sponsor
- University of Oxford
Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade…
- Conditions
- Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma
- Trial name
- NCT02101788
- Testing
- Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
- Where
- 501 sites in United States, United Kingdom
- Volunteers
- 260 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.